A 41-year-old male with IgG kappa multiple myeloma is described. He developed a free gamma heavy chain without an accompanying light chain following highdose chemotherapy and autologous peripheral blood stem cell transplantation. The free gamma heavy chain was detected in serum and urine specimens 2 months after transplant, and eventually evolved into an IgG kappa monoclonal protein with electrophoretic properties similar to the original myeloma protein. Although the origin of the free gamma heavy chain remains uncertain, it was most likely related to the underlying plasma cell malignancy and, therefore, was an early sign of disease relapse. Bone Marrow Transplantation (2001) 27, 663-666. Keywords: multiple myeloma; relapse; autologous stem cell transplantation; heavy chain protein Multiple myeloma is an incurable B cell malignancy accounting for approximately 10% of all hematologic tumors.
Multiple myeloma is an incurable B cell malignancy accounting for approximately 10% of all hematologic tumors. 1 Although alkylating agents have been used for more than 30 years to treat multiple myeloma, median survival does not normally exceed 30 to 36 months. 2 Repeated cycles of high-dose chemotherapy supported by peripheral blood stem cell (PBSC) transplants has resulted in significant improvements in overall and event-free survival of 68 and 43 months, respectively. 3 During regeneration of the B cell compartment following transplantation, monoclonal immunoglobulins (Igs) can often be detected in serum (against a polyclonal background), that appear as multiple discrete bands by protein electrophoresis. 4, 5 These oligoclonal bands are transient and not indicative of relapse or disease progression since they are unrelated to the underlying B cell malignancy. 6 In this report an IgG kappa multiple myeloma patient is described that produced a monoclonal gamma heavy chain without an associated light chain following high-dose chemotherapy and PBSC support. This finding has not been previously described in the literature. Unlike oligoclonal Ig bands that are unrelated to the underlying disease, the free gamma heavy chain in this case was most likely derived from the malignant plasma cell clone, and was an early indicator of disease relapse.
Case report
A 41-year-old man with a complaint of hip pain was seen in April 1998. Radiologic studies revealed a lytic mass with destruction of the posterior right T5 rib. Bone surveys were positive for metastatic disease involving the left pelvis, right chest and skull. The bone marrow was replaced by moderately to well-differentiated plasma cells comprising approximately 98% of the marrow cellularity. Serum protein was elevated at 115 g/l (reference range, 62-80) and protein electrophoresis revealed a restricted peak in the gamma region of 55 g/l (Figure 1a ). An IgG kappa monoclonal protein was detected by immunofixation electrophoresis (Figure 1b) . A diagnosis of stage IIIA multiple myeloma was made. The patient received seven cycles of chemotherapy with VCMP (vincristine, cyclophosphamide, melphalan, prednisone) alternating with VAD (vincristine, adriamycin, dexamethasone). A favorable clinical response was obtained and the concentration of myeloma protein in the serum decreased from 55 g/l to 15 g/l. The patient then received two cycles of induction chemotherapy with cyclophosphamide, etoposide and filgrastim, and PBSCs (CD34 + ) were collected. Complete remission was achieved after the first cycle of induction chemotherapy. He then underwent high-dose chemotherapy with melphalan and autologous PBSC support in January 1999, and again in March 1999.
Two months later the patient complained of shoulder pain. Radiologic studies revealed new lytic lesions. Multiple skin nodules were present on the arm and chest wall and were diagnosed as plasmacytomas. A large cell lymphoid neoplasm, most likely anaplastic plasma cell myeloma, extensively involved the bone marrow. Obliterative interstitial infiltrates were present. The malignant cells exhibited dispersed chromatin, prominent small nucleoli and cytoplasm consistent with plasmacytoid cells at several stages of differentiation. Mitotic figures were numerous. Immunofluorescent studies indicated that 19% of the bone marrow cells expressed cytoplasmic kappa light chain. Serum protein electrophoresis at the time revealed a monoclonal protein of 6 g/l. Surprisingly, immunofixation electrophoresis was positive for a gamma heavy chain without an associated light chain (Figure 2a ). Serum IgG concentrations were elevated at 21.5 g/l (reference range 8.4-16.4), whereas the concentration of kappa light chains was dramatically reduced at 0.87 g/l (reference range 2.3-4.9). The urine contained 2.6 g of protein per 24 h that was exclusively free gamma heavy chain (Figure 2b ). Kappa and lambda light chains were not detectable in the urine (Figure 2b ). The finding of an isolated IgG heavy chain without an associated kappa light chain was puzzling because the patient was originally diagnosed with IgG kappa myeloma. The lack of serum light chain reactivity was verified by repeat immuofixation electrophoresis using anti-kappa and antilambda antisera obtained from two other commercial sources (data not shown).
The patient subsequently received dexamethasone pulsing and thalidomide for disease control. Serum immunofixation electrophoresis after chemotherapy in June was again positive for a free gamma heavy chain. However, an IgG kappa monoclonal protein was also present (Figure 2c) . Interestingly, the IgG kappa monoclonal protein that appeared at this time electrophoresed to a position on the gel similar to that observed for the original IgG kappa monoclonal protein detected in April 1998. This was noteworthy because IgG monoclonal proteins can be detected anywhere in the gamma region and sometimes migrate as far as the beta region, when evaluated by electrophoresis. The urine was positive for only a free gamma heavy chain (Figure 2d) . A month later the free gamma heavy chain completely disappeared from the serum and only an IgG kappa monoclonal protein was detectable (data not shown).
In July 1999 the patient received additional chemotherapy and PBSCs from his 6/6 HLA-matched sibling sister. Sixty days post transplant the patient achieved complete remission. Serum and urine protein studies were negative for a monoclonal protein. Graft-versus-host disease developed on the skin and was controlled by immunosuppressive drugs. A month later there was recurrence of myeloma in the form of plasmacytomas under the skin on the neck and trunk. An IgG kappa monoclonal protein was detected in the serum. The patient received two more cycles of chemotherapy followed by allogeneic stem cell infusions and again achieved complete remission. Last follow-up, 12 months out, the patient remains in complete remission with limited chronic graft-versus-host disease of the skin.
Discussion
We describe a patient with multiple myeloma that developed a free gamma heavy chain monoclonal protein in the serum and urine following high-dose chemotherapy and autologous PBSC transplantation. The isolated heavy chain was detected 2 months after transplantation, persisted for an additional 2 months, and was eventually replaced by an intact IgG kappa monoclonal protein. The IgG kappa monoclonal protein that emerged had an electrophoretic mobility similar to the IgG kappa monoclonal protein at diagnosis, indicative of clinical relapse. The origin of the free gamma heavy chain is unknown. It may have been derived from the original malignant plasma cell clone, or alternatively, a second unrelated clone. Since the free heavy chain was only transiently expressed and of the same isotype as the original monoclonal protein (gamma), it was probably related to the underlying B cell malignancy. Perhaps an unstable mutation occurred as a result of the highdose chemotherapy. Of particular interest was the observation that the bone marrow was positive for cytoplasmic kappa light chain when both the serum and urine were negative for monoclonal Ig light chains. This phenomenon has been observed in cases of non-secretory myeloma 7 and gamma-heavy chain disease, 8 and has been speculated to be due to a block in light chain secretion or a structural abnormality making light chains highly susceptible to extracellular proteolysis.
Heavy chain disease is a rare B cell lymphoproliferative disorder due to genetic alterations in the heavy chain gene resulting in production of a truncated heavy chain, without an associated light chain. 9 This disorder is diagnosed by detecting a free heavy chain in serum and/or urine without an associated light chain. About 100 cases of gamma heavy chain disease have been described and it is frequently associated with Hodgkin's disease, non-Hodgkin's lymphoma and various autoimmune diseases. 9 Gamma heavy chain disease is clinically distinct from multiple myeloma and has a variable clinical course ranging from asymptomatic to rapidly progressive disease. 10 The distinct clinical presentation of gamma heavy chain disease makes it highly unlikely that the case presented herein would be confused with this rare disorder, even in the absence of an appropriate clinical history.
An important aspect of this case is the aggressive nature of the disease. Although a complete response was obtained after high-dose chemotherapy and autologous PBSC transplants, there was evidence of relapse 2 months later. Bone marrow studies at relapse revealed a high (у1) plasma cell labeling index and multiple cytogenetic abnormalities including chromosome 13 deletions. These findings are major prognostic factors that predict poor outcomes in multiple myeloma, 11, 12 and in this case, were associated with shortened progression-free survival.
Following high-dose therapy and hematopoietic cell transplantation for multiple myeloma, oligoclonal Ig bands can appear when disease is monitored by serum immunofixation electrophoresis. The incidence of oligoclonal Ig bands after transplantation has been reported to range from 9 to 73%, and can persist for up to 31 months. 4, 5 These oligoclonal bands are commonly IgG kappa and IgG lambda, although a few cases with IgA and IgM oligoclonal bands have been described. 5 Oligoclonal Ig bands after transplant are due to recovery of the normal B cell compartment and are unrelated to the underlying B cell malignancy. [4] [5] [6] Thus, the presence of oligoclonal Igs should not be considered indicative of disease relapse. In contrast, the presence of a free heavy chain (of the same isotype as the original myeloma protein) without an accompanying light chain, as described herein, is most likely related to the origBone Marrow Transplantation inal disease, and should be interpreted as an early indicator of disease recurrence.
